구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TS-1 |
Overview Company | Takara Bio Inc. |
Overview Modality | CGT |
Overview Target | Pancreatic Cancer Stage III |
Overview Indication | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral vector to express the CD30-specific CAR (CD30 |
MoA Mechanism | inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway |
MoA Biomarker | biomarkers for diagnosing and understanding TS mechanisms |
PK/PD Species | Dog, Mouse |
PK/PD Animal (cat.) | Mouse, Dog, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse |
Toxicology Animal (cat.) | Mouse, Dog, In vitro |
Toxicology Major finding | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Safety signal | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Selected reported efficacy | ORR 72.2% |
Clinical Reported ORR | 72.2% |
Clinical Reported PFS | 9.4 |
Clinical Reported OS | 16.9 |
Clinical Result source | ClinicalTrials.gov NCT03382600 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03382600 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | TS-1 |
Overview Company | Takara Bio Inc. |
Overview Modality | CGT |
Overview Target | Pancreatic Cancer Stage III |
Overview Indication | Pancreatic Cancer Stage III; Pancreatic Cancer Stage IV |
Overview Phase | PHASE_1 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Watch |
Overview Approval status | Investigational |
Technology Vector | retroviral vector to express the CD30-specific CAR (CD30 |
MoA Mechanism | inhibits endometrial cancer cell proliferation, migration, and apoptosis by blocking the PI3K/AKT/mTOR signaling pathway |
MoA Biomarker | biomarkers for diagnosing and understanding TS mechanisms |
PK/PD Species | Dog, Mouse |
PK/PD Animal (cat.) | Mouse, Dog, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Dog, Mouse |
Toxicology Animal (cat.) | Mouse, Dog, In vitro |
Toxicology Major finding | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Safety signal | pneumonitis and skin toxicity were observed, but nonhematological toxicities occurred at ge |
Clinical Selected reported efficacy | ORR 72.2% |
Clinical Reported ORR | 72.2% |
Clinical Reported PFS | 9.4 |
Clinical Reported OS | 16.9 |
Clinical Result source | ClinicalTrials.gov NCT03382600 |
Clinical Program phase | PHASE_1 |
Clinical Trial ref | NCT03382600 |
추천 비교
추천 비교